The answer keyfor CRISPR screens

0.26
Precision when one gold-standard screen checks another
0.30
Replicate agreement once the context-specific effect is isolated
2,217
Published screens in BioGRID ORCS v2.0.18
$19k
Published price of one pooled genome-wide screen

Hundreds of hits.
Budget for twelve.

A screen can return hundreds of candidates. Effect size, guide support and technical artifacts all matter when choosing follow-up experiments.

SplicR ranks a screen's candidates by which survive contact with a second experiment. Across 124 held-out screen pairs, nine of its top ten reproduced in an independent screen, against seven for the screen's own effect size.

01What SplicR does
Hit ReportDiscovery MapScreen PlannerTruth LoopAtlasConnect
Hit ReportDiscovery MapScreen PlannerTruth LoopAtlasConnect
Copy-number flagsGuide concordanceFrequent hittersOutcome recordsProvenance
Copy-number flagsGuide concordanceFrequent hittersOutcome recordsProvenance

The science
behind the analysis

See the pipeline
01
Ingest
02
Count and QC
03
Call hits
04
Flag artifacts
05
Review evidence
0.26
Precision in one processed dependency comparison
5.4%
Of Avana guides perfectly target more than one gene

SplicR preserves method-specific statistics and reports their context and limitations. Independent validation-success probabilities are not available.

01

SplicR makes screen evidence inspectable, with measured results and explicit limits.

1,349
Training screens
334
Public test screens
0.160369
Research router AnDCG@100
0.163091
Published ensemble AnDCG@100

The research router did not improve on the published ensemble and was not promoted. Its paired uncertainty interval includes zero. These are retrospective ranking scores, not percentages of biological accuracy or independent validation.

Source: AssayBench test set, 334 screens published after 2021

  1. 01Ingest
  2. 02Count and QC
  3. 03Call hits
  4. 04Flag artifacts
  5. 05Review evidence

One pipeline.
Explicit assumptions.

The local engine checks inputs, runs applicable statistical methods and records evidence. Atlas entries retain their original methods; they are not uniformly reprocessed or calibrated.

See the pipeline

Screens

Redefined.

Recorded effects, inspectable evidence and explicit uncertainty. Independent prospective validation remains outstanding.

2,217
ORCS v2.0.18 reference screens
1,349
AssayBench training screens
334
Public test screens replayed
Measured analysis

A result you can inspect, including its limits.

This CHD1L row comes from the actual GSE145743 processed-count audit. It was not significant under the corrected q < 0.1 rule. No probability of successful validation has been assigned.

The earlier raw-read analysis used a different input and reported a different rank. It is retained in the research history and is not interchangeable with this result.

GSE145743, olaparib versus DMSO

CHD1L

Observed log₂ fold change
-1.5486
MAGeCK depletion FDR
0.559153
Two-family adjusted FDR
1.000
DrugZ FDR, unpaired
0.161

QC failed under the current dropout/depth criteria. Those criteria are not universal assay-quality standards. This single case does not establish validation precision.

Inspect methods, source and audit

Bring us a finished screen.

Discuss a blinded evaluation with us. Predictions, outcome definitions and the analysis plan must be frozen before independent validation outcomes are revealed. This workflow still requires a laboratory partner.